How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Elliott Investment Takes ~3% Stake in Daikin, Pushes for Buybacks and Strategic Overhaul 
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
DEEPX Partners with Hyundai to Power Next-Gen AI Robots Ahead of IPO 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
Goldman Sachs FICC Revenue Falls 10% Amid Iran War Market Volatility 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake 
Federal Agencies Secretly Test Anthropic's AI Despite Trump Administration Ban 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
KKR's $820M Investment Fuels Samsung SDS AI Expansion, Sending Group Shares Soaring 
CSN's Cement Unit Sale Could Exceed $2 Billion as Global Giants Circle 
Want to cut your energy bills? Here’s how five experts are doing it 
Federal Judge Dismisses DOJ Lawsuit Attempting to Block Hawaii's Climate Case Against Oil Giants 
EMERYVILLE, Calif., May 31, 2017 -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that Michael P. Smith, Executive Vice President, Chief Financial Officer & Treasurer and Secretary, will present a corporate overview at the Jefferies 2017 Global Healthcare Conference, taking place on June 6-9, 2017, in New York, NY.
Zogenix Presentation Details
| Date: | Wednesday, June 7, 2017 |
| Time: | 2:00 pm Eastern Time / 11:00 am Pacific Time |
The presentation will be webcast live and archived for 30 days on Zogenix's Investor Relations website at ir.zogenix.com.
About Zogenix
Zogenix, Inc. (Nasdaq:ZGNX) is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.
For more information, visit www.zogenix.com.
CONTACT: Investors: Andrew McDonald Founding Partner, LifeSci Advisors LLC 646-597-6987 | [email protected]
